NASDAQ:SNSS - Sunesis Pharmaceuticals Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $1.28 +0.03 (+2.40 %) (As of 03/26/2019 06:23 AM ET)Previous Close$1.25Today's Range$1.03 - $1.3352-Week Range$0.20 - $3.08Volume2.69 million shsAverage Volume831,139 shsMarket Capitalization$86.50 millionP/E Ratio-1.71Dividend YieldN/ABeta2.43 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sunesis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company also engages in developing TAK-580, a pan-Raf inhibitor program in combination with various anticancer agents for the treatment of advanced solid tumor cancers in adult patients; SNS-510, which is in preclinical pharmacology and toxicology studies for the treatment of solid tumor and hematologic malignancies; and vosaroxin, an anticancer quinolone derivative for the treatment of acute myeloid leukemia (AML). In addition, it is developing vosaroxin, which is in Phase 2 trial with decitabine for treatment of diagnosed acute AML or myelodysplastic syndrome (MDS); Phase 1/2 trial with azacitidine for treatment of MDS; Phase 2 trial with infusional cytarabine for treatment of AML; Phase 1/2 trial in adult patients with previously treated intermediate-2 or high-risk MDS; and Phase 1/2 trial with cytarabine tested as consolidation therapy. The company has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of phosphoinositide-dependent kinase-1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California. Receive SNSS News and Ratings via Email Sign-up to receive the latest news and ratings for SNSS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SNSS Previous Symbol CUSIP86732860 CIK1061027 Webwww.sunesis.com Phone650-266-3500Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.34Price-To-Earnings Trailing P/E Ratio-1.71 Forward P/E Ratio-1.91 P/E GrowthN/A Sales & Book Value Annual Sales$240,000.00 Price / Sales360.42 Cash FlowN/A Price / Cash FlowN/A Book Value($0.45) per share Price / Book-2.84Profitability EPS (Most Recent Fiscal Year)($0.75) Net Income$-26,610,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-123.92%Miscellaneous EmployeesN/A Outstanding Shares67,578,000Market Cap$86.50 million Next Earnings Date5/14/2019 (Estimated) OptionableOptionable Sunesis Pharmaceuticals (NASDAQ:SNSS) Frequently Asked Questions What is Sunesis Pharmaceuticals' stock symbol? Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS." How were Sunesis Pharmaceuticals' earnings last quarter? Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) issued its quarterly earnings results on Thursday, March, 7th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.06. View Sunesis Pharmaceuticals' Earnings History. When is Sunesis Pharmaceuticals' next earnings date? Sunesis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, May 14th 2019. View Earnings Estimates for Sunesis Pharmaceuticals. What price target have analysts set for SNSS? 3 Wall Street analysts have issued 12-month target prices for Sunesis Pharmaceuticals' stock. Their forecasts range from $0.50 to $6.00. On average, they expect Sunesis Pharmaceuticals' stock price to reach $3.25 in the next year. This suggests a possible upside of 153.9% from the stock's current price. View Analyst Price Targets for Sunesis Pharmaceuticals. What is the consensus analysts' recommendation for Sunesis Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sunesis Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Sunesis Pharmaceuticals. Has Sunesis Pharmaceuticals been receiving favorable news coverage? News articles about SNSS stock have trended somewhat positive on Tuesday, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sunesis Pharmaceuticals earned a daily sentiment score of 0.8 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the near future. Who are some of Sunesis Pharmaceuticals' key competitors? Some companies that are related to Sunesis Pharmaceuticals include MediciNova (MNOV), Osmotica Pharmaceuticals (OSMT), Karyopharm Therapeutics (KPTI), Insys Therapeutics (INSY), AC Immune (ACIU), Kezar Life Sciences (KZR), Kindred Biosciences (KIN), American Brivision (Holding) (ABVC), Protagonist Therapeutics (PTGX), Geron (GERN), Syros Pharmaceuticals (SYRS), Minerva Neurosciences (NERV), Verrica Pharmaceuticals (VRCA), Aduro BioTech (ADRO) and Merus (MRUS). What other stocks do shareholders of Sunesis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sunesis Pharmaceuticals investors own include NVIDIA (NVDA), Exelixis (EXEL), SLS International (SLS), Conatus Pharmaceuticals (CNAT), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Sarepta Therapeutics (SRPT), Micron Technology (MU), Synergy Pharmaceuticals (SGYP) and Progenics Pharmaceuticals (PGNX). Who are Sunesis Pharmaceuticals' key executives? Sunesis Pharmaceuticals' management team includes the folowing people: Mr. Dayton Misfeldt, Interim CEO & Director (Age 45)Mr. William P. Quinn, Sr. VP of Fin. & Corp. Devel. and CFO (Age 48)Mr. Daniel N. Swisher Jr., Strategic Advisor (Age 56)Mr. Gene C. Jamieson, VP of Technical OperationsDr. Judith A. Fox, Chief Scientific Officer Who are Sunesis Pharmaceuticals' major shareholders? Sunesis Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Aisling Capital Management LP (6.95%), Rhenman & Partners Asset Management AB (1.01%) and Great Point Partners LLC (0.85%). Company insiders that own Sunesis Pharmaceuticals stock include Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Institutional Ownership Trends for Sunesis Pharmaceuticals. Which major investors are selling Sunesis Pharmaceuticals stock? SNSS stock was sold by a variety of institutional investors in the last quarter, including Great Point Partners LLC and Rhenman & Partners Asset Management AB. View Insider Buying and Selling for Sunesis Pharmaceuticals. Which major investors are buying Sunesis Pharmaceuticals stock? SNSS stock was acquired by a variety of institutional investors in the last quarter, including Aisling Capital Management LP. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Dayton Misfeldt, Mpm Oncology Impact Management and William P Quinn. View Insider Buying and Selling for Sunesis Pharmaceuticals. How do I buy shares of Sunesis Pharmaceuticals? Shares of SNSS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sunesis Pharmaceuticals' stock price today? One share of SNSS stock can currently be purchased for approximately $1.28. How big of a company is Sunesis Pharmaceuticals? Sunesis Pharmaceuticals has a market capitalization of $86.50 million and generates $240,000.00 in revenue each year. The biopharmaceutical company earns $-26,610,000.00 in net income (profit) each year or ($0.75) on an earnings per share basis. What is Sunesis Pharmaceuticals' official website? The official website for Sunesis Pharmaceuticals is http://www.sunesis.com. How can I contact Sunesis Pharmaceuticals? Sunesis Pharmaceuticals' mailing address is 395 OYSTER POINT BOULEVARD SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at 650-266-3500 or via email at [email protected] MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 334 (Vote Outperform)Underperform Votes: 343 (Vote Underperform)Total Votes: 677MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe SNSS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNSS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/26/2019 by MarketBeat.com StaffFeatured Article: Why Invest in Dividend Achievers?